SCHEMBL4129954

SCHEMBL4129954

Nc1ccc2[nH]c3cc(C(F)(F)F)ccc3c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 17/20 1.00
CHUK O15111 1/20 0.53
AR P10275 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124635 0.93 KIF11 (0.88) KIF11CHUKAR
SCHEMBL4135726 0.91 KIF11 (1.00) KIF11AR
SCHEMBL4123985 0.91 KIF11 (0.84) KIF11CHUKAR
SCHEMBL19785406 0.84 KIF11 (0.81) KIF11
SCHEMBL30975189 0.82 KIF11 (0.68) KIF11AR
SCHEMBL5914553 0.82 KIF11 (0.68) KIF11AR
SCHEMBL13772407 0.80 KIF11 (0.88) KIF11CHUK
SCHEMBL29507666 0.80 KIF11 (0.81) KIF11CHUK
SCHEMBL412032 0.80 KIF11 (0.81) KIF11CHUK
SCHEMBL4126997 0.79 KIF11 (1.00) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170882-A1 Methods and compositions CYTOKINETICS, INCORPORATED 2009-07-02 US claimed
EP-1771176-A2 METHODS AND COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-11 EP claimed
WO-2006005063-A2 METHODS AND COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-01-12 WO claimed
US-20090170882-A1 Methods and compositions CYTOKINETICS, INCORPORATED 2009-07-02 US disclosed
US-20090170882-A1 Methods and compositions CYTOKINETICS, INCORPORATED 2009-07-02 US disclosed
US-20090170882-A1 Methods and compositions CYTOKINETICS, INCORPORATED 2009-07-02 US disclosed
EP-1771176-A2 METHODS AND COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-11 EP disclosed
WO-2006005063-A2 METHODS AND COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170882-A1 Methods and compositions KIF5B, KIF5C, KIF2C KIF11 10/4885CHUK 3598/4885AR 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.